The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Van Schooten, TS (Author) Other; Derks, S (Author) Other; Jimenez-Marti, E (Author) Other; Carneiro F (Author) FMUP; Figueiredo C (Author) FMUP; Ruiz, E (Author) Other; Alsina, M (Author) Other; Molero, C (Author) Other; Garrido, M (Author) Other; Riquelme, A (Author) Other; Caballero, C (Author) Other; Lezcano, E (Author) Other; O'Connor, JM (Author) Other; Esteso, F (Author) Other; Farres, J (Author) Other; Mas, JM (Author) Other; Lordick, F (Author) Other; Vogt, J (Author) Other; Cardone, A (Author) Other; Girvalaki, C (Author) Other; Cervantes, A (Author) Other; Fleitas, T (Author) Other

Journal

Title: BMC Cancer

Vol. 22

ISSN: 1471-2407

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 0 Citations

Scopus

Other information

Authenticus ID: P-00W-S8Q

DOI: 10.1186/s12885-022-09689-9

Abstract (EN): Background: Gastric Cancer (GC) is the fourth most deadly cancer worldwide. Enhanced understanding of its key epidemiological and molecular drivers is urgently needed to lower the incidence and improve outcomes. Furthermore, tumor biology in European (EU) and Latin American (LATAM) countries is understudied. The LEGACy study is a Horizon 2020 funded multi-institutional research approach to 1) detail the epidemiological features including risk factors of GC in current time and 2) develop cost-effective methods to identify and integrate biological biomarkers needed to guide diagnostic and therapeutic approaches with the aim of filling the knowledge gap on GC in these areas. Methods: This observational study has three parts that are conducted in parallel during 2019-2023 across recruiting centers from four EU and four LATAM countries: Part 1) A case-control study (800 cases and 800 controls) using L questionnaires on candidate risk factors for GC, which will be correlated with clinical, demographic and epidemiological parameters. Part 2) A case-control tissue sampling study (400 cases and 400 controls) using proteome, genome, microbiome and immune analyses to characterize advanced (stage III and IV) GC. Patients in this part of the study will be followed over time to observe clinical outcomes. The first half of samples will be used as training cohort to identify the most relevant risk factors and biomarkers, which will be selected to propose cost-effective diagnostic and predictive methods that will be validated with the second half of samples. Part 3) An educational study, as part of our prevention strategy (subjects recruited from the general public) to test and disseminate knowledge on GC risk factors and symptoms by a questionnaire and informative video. Patients could be recruited for more than one of the three LEGACy studies. Discussion: The LEGACy study aims to generate novel, in-depth knowledge on the tumor biological characteristics through integrating epidemiological, multi-omics and clinical data from GC patients at an EU-LATAM partnership. During the study, cost-effective panels with potential use in clinical decision making will be developed and validated.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8